Find your path to Clare
99 people in our graph share verified history with Clare — schools, employers, funds. One of them is your warm intro.
About
Clare Wareing is the founder and CEO of Cumulus Oncology, a company focused on oncology drug development through partnerships and business development-led deals. She has over 30 years of experience in oncology drug development and has founded, scaled, and exited companies in clinical development, contributing to programs that led to drug approvals. Cumulus Oncology has raised $25 million to date and holds a portfolio that includes a PARG inhibitor, a GPR68 negative allosteric modulator with separate intellectual property covering oncology and IBD, and a KRAS G12R inhibitor.
CEO at Cumulus Oncology
Intro paths
In turn, Clare can intro founders to Cumulus Oncology's investors below.
Cumulus Oncology's investors · 5
Co-founders at Cumulus Oncology
Experience
- Cumulus OncologyFounder and CEO Cumulus Oncologycurrent2017 — presentEdinburgh, United Kingdom
- IP Oncology LtdFounder2014 — 2017Edinburgh, United Kingdom
- ChilternChief Development Officer2014 — 2016Edinburgh, United Kingdom
- Ockham OncologyChief Scientific Officer2012 — 2014
- Nexus OncologyFounder1999 — 2012
- Nexus OncologyCEO1999 — 2012
- Ilex OncologyDirector of Operations1997 — 1998
- QuintilesClinical Operations Manager1995 — 1996
- Syntex Research Centre, EdinburghClinical Research Associae1990 — 1995
Skills & more
+11 more
Phase IMedical DevicesPharmacovigilanceClinical OperationsTherapeutic AreasBiopharmaceuticalsImmunologyEDCCTMSCROPharmaceutical IndustryLanguages French
From Clare's professional profile.
Frequently asked questions
- Who is Clare Wareing?
- Clare Wareing is the founder and CEO of Cumulus Oncology, a company focused on oncology drug development through partnerships and business development-led deals. She has over 30 years of experience in oncology drug development and has founded, scaled, and exited companies in clinical development, contributing to programs that led to drug approvals. Cumulus Oncology has raised $25 million to date and holds a portfolio that includes a PARG inhibitor, a GPR68 negative allosteric modulator with separate intellectual property covering oncology and IBD, and a KRAS G12R inhibitor.
- Where does Clare Wareing work?
- Clare Wareing is CEO at Cumulus Oncology.
- Where did Clare Wareing go to school?
- Clare Wareing studied at The University of Edinburgh (PhD, Multidrug resistance in solid tumours).
Same school
Shared employers
Also worked at Cumulus Oncology2
Also worked at Chiltern1
Also worked at Quintiles84
+ 78 more